Atea Pharmaceuticals (AVIR) Q2 2024 earnings summary

Executive summary

• Achieved full enrollment in global Phase 3 SUNRISE-3 COVID-19 and Phase 2 HCV trials, with all patients completing last scheduled visits; topline results for both expected in the second half of 2024 and HCV Phase 3 program preparation underway.

• Cash, cash equivalents, and marketable securities totaled $502.2 million as of June 30, 2024, expected to fund operations into 2027.

• Selected a fixed-dose combination tablet for HCV, reducing daily pill burden and supporting Phase 3 and commercialization plans.

• Presented positive HCV data at EASL, supporting best-in-class potential for bemnifosbuvir and ruzasvir.

Financial highlights

• Q2 2024 net loss was $40.5 million, compared to $28.2 million in Q2 2023; six-month net loss was $103.7 million, up from $63.7 million year-over-year.

• Research and development expenses increased year-over-year, reaching $34.7 million in Q2 2024, mainly due to clinical trial advancement.

• General and administrative expenses decreased to $12.2 million in Q2 2024 from $13.2 million in Q2 2023, mainly due to lower professional fees.

• Interest income and other, net, was $6.6 million in Q2 2024, down from $7.3 million in Q2 2023, reflecting lower investment balances.

• Cash, cash equivalents, and marketable securities decreased to $502.2 million at June 30, 2024, from $578.1 million at December 31, 2023.

Outlook and guidance

• Topline results for SUNRISE-3 COVID-19 trial and full Phase 2 HCV SVR12 data expected in the second half of 2024; NDA submissions for both programs targeted for year-end 2024.

• Phase 3 HCV program initiation targeted for late 2024, pending regulatory discussions.

• R&D spending will fluctuate as current studies complete and new programs initiate.

• Cash runway expected to fund operations into 2027.